Updated on : 04-04-2018
The Ministry of Health and Sport, Food and Drug Administration Department investigated and discovered non-standardized drug in the market. It has been informed to the companies to withdraw them from the market at the relevant states and divisions. Therefore, in the future, the following non-standardize drug distribution will not be allowed in the market and the investigation process will do on the distribution of them-
No. |
Description |
Name of Manufacturer |
Batch No. |
1 |
Flumyan 500 Capsule(Flucloxacillin Sodium BP eq. to Flucloxacilin 500mg) |
India |
FMD/ 6001 |
2 |
Flumyan 250 Capsule (Flucloxacillin Sodium BP eq.to Flucloxacillin 250 mg) |
Maan Pharmaceuticals Ltd, India |
FMT/ 6001 |
3. |
Swifrucid 40 Tablet (Frusemide BP 40mg) |
Swiss Pharma Pvt. Ltd, India |
6273 |
4. |
Pai Cotokin Tablet (Artemether 20mg, Lumefantrine 120 mg) |
Ningbo Shuangwei Pharmaceutical Co., Ltd, PR China |
0805 |
5. |
Amnacloxa Capsule (Ampicillin Trihydrate BP eq.to Ampicillin 250mg, Cloxacillin Sodium BP eq.to Cloxacillin 250mg) |
AMN Lifesciences Pvt. Ltd, India |
6022 |
Title | Category | Created On |
---|---|---|
Non Standardized drug | SPS | 04-04-2018 |
မိုရေးအကောက်ခွန်ဌာနက အိန္ဒိယ ကွမ်းသီးကုန်သည်များထံမှ ၄၀ ရာခိုင်နှုန်း အခွန်ကောက်ခံမှုကြောင့် တမူးနယ်စပ်မှ ကွမ်းသီး တင်ပို့မှုကျဆင်း | General | 19-01-2017 |
ဓာတ်မြေသြဇာဈေးကွက် အရောင်းပုံမှန်ရှိ | General | 19-01-2017 |
ဒီတစ်ပတ်မြေသြဇာတန်ချိန် ၄၀ဝ၀ဝ နီးပါးဝင် | General | 19-01-2017 |
ဘိလပ်မြေဈေးကွက်ရောင်းအားတက် | General | 18-01-2017 |